Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

MaaT013

Phase 2Small molecule

MaaT013 is one of 75 small molecule programs targeting Melanoma. It is currently in Phase 2.

2

Indications

3

Total Trials

1

Active Trials

74

Competitors

Pipeline

Status by Indication[3][1]

Indication

MelanomaActive, not recruiting

Graft Versus Host DiseaseActive, not recruiting

MelanomaPhase 2

Active, not recruiting

Graft Versus Host DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Leukine

Fabhalta

Intismeran Autogene

Epacadostat

Masitinib

Peg-IFN Alfa-2b

GSK2118436

Zelboraf

CConrado Roberto Hoffmann Filho

Intron a

Opdualag

Bristol-Myers Squibb

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Melanoma1 trial

Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04988841·70 enrolled

Refractory1 trial

MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients

Active, not recruiting·MMaaT Pharma·Phase 3·NCT04769895·66 enrolled

Graft Versus Host Disease1 trial

Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease

Available·MMaaT Pharma··NCT04768907

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for MaaT013. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MaaT013 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MaaT013. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — MaaT Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMaaT Pharma

Related News